Dr. Reddy's Laboratories

Company snapshot

Each of us at Dr. Reddy’s Laboratories in USA is driven by the urgent need for more affordable, innovative medications. We are in the business of good health, determined in our efforts to accelerate access to affordable medicines. With every product launch, we’re making healthcare more affordable while delivering value to the pharmacy. Today, there are millions of people who have benefited from the

• 2 approved product(s) across US/EU regulatory metadata.
• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Dr. Reddy's Laboratories. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Dr. Reddy's Laboratories.

1. Jun 8, 2026 Clinical update

   AB-01-004 — Phase 3

View all clinical trial activity →

• What is Dr. Reddy's Laboratories?

  Dr Reddy''s Laboratories is a pharma organization headquartered in AU. Primary therapeutic focus areas include Rheumatoid Arthritis. NovaPharmaNews links 1 clinical program(s), 2 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and

• Is Dr. Reddy's Laboratories publicly traded?

  Dr. Reddy's Laboratories appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Dr. Reddy's Laboratories develop or market?

  We link 7 drug profile(s) where Dr. Reddy's Laboratories is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/reddy-holding-gmbh#company-drugs.

• What are the latest developments for Dr. Reddy's Laboratories?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Dr. Reddy's Laboratories focus on?

  Dr. Reddy's Laboratories focuses on Rheumatoid Arthritis based on our analysis of their pipeline programs and drug development activities.